Connection
Todd Pitts to Transplantation, Heterologous
This is a "connection" page, showing publications Todd Pitts has written about Transplantation, Heterologous.
|
|
Connection Strength |
|
|
|
|
|
0.141 |
|
|
|
-
Lanis JM, Lewis MS, Strassburger H, Larsen K, Bagby SM, Dominguez ATA, Mar?n-Jim?nez JA, Pelanda R, Pitts TM, Lang J. Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors. J Vis Exp. 2022 12 16; (190).
Score: 0.052
-
Bagby S, Messersmith WA, Pitts TM, Capasso A, Varella-Garcia M, Klauck PJ, Kim J, Tan AC, Eckhardt SG, Tentler JJ, Arcaroli J. Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies. J Vis Exp. 2016 09 30; (115).
Score: 0.034
-
Flanigan SA, Pitts TM, Newton TP, Kulikowski GN, Tan AC, McManus MC, Spreafico A, Kachaeva MI, Selby HM, Tentler JJ, Eckhardt SG, Leong S. Overcoming IGF1R/IR resistance through inhibition of MEK signaling in colorectal cancer models. Clin Cancer Res. 2013 Nov 15; 19(22):6219-29.
Score: 0.028
-
Bradshaw-Pierce EL, Pitts TM, Kulikowski G, Selby H, Merz AL, Gustafson DL, Serkova NJ, Eckhardt SG, Weekes CD. Utilization of quantitative in vivo pharmacology approaches to assess combination effects of everolimus and irinotecan in mouse xenograft models of colorectal cancer. PLoS One. 2013; 8(3):e58089.
Score: 0.027
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|